PRKDC and cancer: Although some promising preclinical and early-phase clinical results have been reported recently [15,22,24,25,26], the precise management of DNA-PKcs-based therapy for cancer patients remains a challenge due to the physiological role of DNA-PKcs and the lack of biomarkers that predict response to DNA-PKcs inhibitors.